DoW Prostate Cancer, Idea Development Award

The Prostate Cancer Research Program Idea Development Award is administered by the Defense Health Agency through the Congressionally Directed Medical Research Programs. This initiative is part of a long-standing federal investment in prostate cancer research, which has received billions in appropriations since its establishment in 1997. The program is designed to stimulate innovative, high-impact research that advances the understanding, treatment, and overall management of prostate cancer, particularly in populations such as service members, veterans, and their families. The award emphasizes transformative ideas that can significantly contribute to reducing mortality and improving survivorship outcomes. The primary objective of the Idea Development Award is to support novel research concepts that challenge existing paradigms or introduce entirely new approaches to prostate cancer research. Applicants are required to align their proposed research with one of several overarching challenges defined for the program. These challenges include improving survivorship and quality of life, developing or enhancing treatments for lethal prostate cancer, improving clinical care, and advancing the biological understanding of disease progression. The program encourages multidisciplinary collaboration and the use of innovative methodologies, including data science and translational approaches. Funding is provided through grants with distinct categories for established investigators and new investigators. Established investigators may request up to 1.7 million dollars over a maximum period of three years, while new investigators may request up to 2.1 million dollars over up to four years. The program anticipates funding approximately 18 awards across both categories, with a total program allocation of approximately 34.6 million dollars. Allowable costs include direct and indirect research expenses, with restrictions such as the prohibition of clinical trial costs and limits on travel funding. Cost sharing is not required, which lowers barriers to entry for eligible applicants. Eligibility is broad and inclusive, allowing applications from domestic and international organizations, including for-profit and nonprofit entities, public and private institutions, and government organizations. Principal investigators must be affiliated with an eligible organization and demonstrate independence in managing research. Special eligibility criteria apply to new investigators, including career stage limitations and requirements to collaborate with experienced prostate cancer researchers. Each investigator may submit only one application as a principal investigator, and must select either the new or established investigator category. The application process is a two-step submission requiring a pre-application and a full application. The pre-application consists of a letter of intent submitted through the Electronic Biomedical Research Application Portal. The full application must then be submitted through either Grants.gov or eBRAP depending on the applicant’s organizational type. Required components include a detailed project narrative, technical and lay abstracts, supporting documentation, statements of innovation and impact, and various administrative forms. The process requires careful coordination of multiple documents and adherence to strict formatting and submission requirements. Applications undergo a rigorous two-tier review process. The first tier is peer review, which evaluates scientific and technical merit based on criteria such as innovation, impact, research strategy, and team qualifications. The second tier is programmatic review, which assesses alignment with program priorities and overall portfolio balance. Review timelines include peer review in late 2026 and programmatic review in early 2027, with funding decisions expected thereafter. Successful applicants receive notification through the eBRAP system and must comply with post-award reporting and regulatory requirements. Key deadlines for the current cycle include a pre-application submission deadline of August 12, 2026, and a full application deadline of September 2, 2026. Awards are expected to be finalized by September 30, 2027, with funds available through 2032. Applicants are strongly encouraged to begin preparation early due to the complexity of registration and submission systems. Technical support is available through eBRAP and Grants.gov help desks, which provide assistance with submission processes and system requirements.

Emphasize innovation and high impact alignment with overarching challenges demonstrate strong scientific rationale and feasibility include multidisciplinary collaboration and clearly articulate long term clinical relevance